Real-World Data to Advance Glomerular Disease Care.
作者信息
Freeman Natasha S, Bomback Andrew S
机构信息
Division of Nephrology, Department of Medicine, Columbia University Irving Medical Center, New York, New York; and David Koch Jr. Glomerular Kidney Center, Columbia University Irving Medical Center, New York, New York.
出版信息
J Am Soc Nephrol. 2025 Jun 5;36(7):1246-8. doi: 10.1681/ASN.0000000758.
Abstract
摘要
相似文献
1
Real-World Data to Advance Glomerular Disease Care.推动肾小球疾病治疗的真实世界数据。
J Am Soc Nephrol. 2025 Jun 5;36(7):1246-8. doi: 10.1681/ASN.0000000758.
2
Regression of superficial glomerular podocyte injury in type 2 diabetic rats with overt albuminuria: effect of angiotensin II blockade.2 型糖尿病伴显性白蛋白尿大鼠肾小球脏层上皮细胞损伤的消退：血管紧张素 II 阻断的作用。
J Hypertens. 2010 Nov;28(11):2289-98. doi: 10.1097/HJH.0b013e32833dfcda.
3
Podocyte-secreted angiopoietin-like-4 mediates proteinuria in glucocorticoid-sensitive nephrotic syndrome.足细胞分泌的血管生成素样蛋白 4 在糖皮质激素敏感型肾病综合征中的蛋白尿形成中起介导作用。
Nat Med. 2011 Jan;17(1):117-22. doi: 10.1038/nm.2261. Epub 2010 Dec 12.
4
Prognostic Impact of Proteinuria at Manifestation in Adult Nephrotic Syndrome Patients: Insights from a Prospective Cohort Study.成人肾病综合征患者发病时蛋白尿的预后影响：一项前瞻性队列研究的见解
Cureus. 2024 Jun 11;16(6):e62143. doi: 10.7759/cureus.62143. eCollection 2024 Jun.
5
Nephrotic urine prevents increased rat glomerular albumin permeability induced by serum from the same patient with idiopathic nephrotic syndrome.肾病性尿液可防止来自同一名特发性肾病综合征患者血清诱导的大鼠肾小球白蛋白通透性增加。
Nephrol Dial Transplant. 2003 Apr;18(4):689-93. doi: 10.1093/ndt/gfg013.
6
Clinicopathological Analysis of Glomerular Disease of Adult Onset Nephrotic Syndrome in an Indian Cohort- A Retrospective Study.印度队列中成人起病肾病综合征肾小球疾病的临床病理分析——一项回顾性研究
J Clin Diagn Res. 2017 May;11(5):EC25-EC30. doi: 10.7860/JCDR/2017/24836.9878. Epub 2017 May 1.
7
Serum D-dimer concentrations in nephrotic syndrome track with albuminuria, not estimated glomerular filtration rate.肾病综合征患者的血清 D-二聚体浓度与蛋白尿相关，而与估计肾小球滤过率无关。
Am J Nephrol. 2012;36(6):554-60. doi: 10.1159/000345475. Epub 2012 Dec 5.
8
Decreased Podocyte Vesicle Transcytosis and Albuminuria in C-Terminal Deficiency Mice with Puromycin-Induced Nephrotic Syndrome.嘌呤霉素诱导的肾病综合征模型中足细胞 C 端缺失导致的囊泡转位减少和蛋白尿。
Int J Mol Sci. 2021 Dec 14;22(24):13412. doi: 10.3390/ijms222413412.
9
Selective albuminuria via podocyte albumin transport in puromycin nephrotic rats is attenuated by an inhibitor of NADPH oxidase.嘌呤霉素肾病大鼠足细胞白蛋白转运导致的选择性白蛋白尿，可被 NADPH 氧化酶抑制剂减弱。
Kidney Int. 2011 Dec;80(12):1328-38. doi: 10.1038/ki.2011.282. Epub 2011 Aug 17.
10
[Nephrotic syndrome and other high-level proteinuria].[肾病综合征及其他高水平蛋白尿]
Rev Med Suisse. 2022 Mar 2;18(771):370-378. doi: 10.53738/REVMED.2022.18.771.370.
本文引用的文献
1
Long-Term Outcomes in Nephrotic Syndrome by Kidney Biopsy Diagnosis and Proteinuria.根据肾活检诊断和蛋白尿情况看肾病综合征的长期预后
J Am Soc Nephrol. 2025 Apr 17;36(7):1398-1413. doi: 10.1681/ASN.0000000610.
2
Autoantibodies Targeting Nephrin in Podocytopathies.足细胞病相关的 Nephrin 自身抗体
N Engl J Med. 2024 Aug 1;391(5):422-433. doi: 10.1056/NEJMoa2314471. Epub 2024 May 25.
3
Long-Term Outcomes in IgA Nephropathy.IgA 肾病的长期预后。
Clin J Am Soc Nephrol. 2023 Jun 1;18(6):727-738. doi: 10.2215/CJN.0000000000000135. Epub 2023 Apr 13.
4
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases.KDIGO 2021肾小球疾病管理临床实践指南。
Kidney Int. 2021 Oct;100(4S):S1-S276. doi: 10.1016/j.kint.2021.05.021.
5
Primary Nephrotic Syndrome and Risks of ESKD, Cardiovascular Events, and Death: The Kaiser Permanente Nephrotic Syndrome Study.原发性肾病综合征与终末期肾病、心血管事件和死亡风险：凯撒永久肾病综合征研究。
J Am Soc Nephrol. 2021 Sep;32(9):2303-2314. doi: 10.1681/ASN.2020111583. Epub 2021 Jun 18.
6
Proteinuria Reduction and Kidney Survival in Focal Segmental Glomerulosclerosis.局灶节段性肾小球硬化症患者的蛋白尿减少与肾脏存活率。
Am J Kidney Dis. 2021 Feb;77(2):216-225. doi: 10.1053/j.ajkd.2020.04.014. Epub 2020 Aug 10.
7
Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency.白蛋白尿和肾小球滤过率（GFR）变化作为慢性肾脏病（CKD）早期临床试验的终点：美国国家肾脏基金会与美国食品和药物管理局（FDA）及欧洲药品管理局（EMA）合作举办的科学研讨会
Am J Kidney Dis. 2020 Jan;75(1):84-104. doi: 10.1053/j.ajkd.2019.06.009. Epub 2019 Aug 28.
8
Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy.蛋白尿减少作为 IgA 肾病试验的替代终点。
Clin J Am Soc Nephrol. 2019 Mar 7;14(3):469-481. doi: 10.2215/CJN.08600718. Epub 2019 Jan 11.
9
Idiopathic Nephrotic Syndrome: Characteristics and Identification of Prognostic Factors.特发性肾病综合征：特征及预后因素的识别
J Clin Med. 2018 Sep 9;7(9):265. doi: 10.3390/jcm7090265.
Zotero 插件